Biohaven (BHVN) Projected to Announce Earnings on Monday

Biohaven (NYSE:BHVN) is expected to be announcing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of ($0.7833) per share and revenue of $63.64 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 7:00 AM ET.

Biohaven (NYSE:BHVN) last announced its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, analysts expect Biohaven to post ($3.03) EPS for the current fiscal year and ($2.63) EPS for the next fiscal year.

Biohaven Stock Performance

Shares of BHVN stock opened at $15.76 on Monday. The company has a debt-to-equity ratio of 21.23, a quick ratio of 3.05 and a current ratio of 3.05. The firm’s 50 day moving average price is $13.63 and its 200-day moving average price is $12.24. Biohaven has a one year low of $7.48 and a one year high of $18.24. The firm has a market cap of $2.38 billion, a P/E ratio of -4.08 and a beta of 1.35.

Analyst Upgrades and Downgrades

BHVN has been the subject of a number of research analyst reports. Wall Street Zen upgraded Biohaven from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. TD Cowen reiterated a “buy” rating on shares of Biohaven in a research note on Wednesday, August 26th. Raymond James Financial restated a “strong-buy” rating on shares of Biohaven in a research note on Thursday, October 8th. Citigroup reaffirmed a “buy” rating on shares of Biohaven in a research report on Friday, September 18th. Finally, Morgan Stanley raised their price objective on shares of Biohaven from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Biohaven currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.94.

Biohaven Company Profile

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.